MG
AXDX

Michael Gelband’s Accelerate Diagnostics AXDX Stock Holding History

Michael Gelband’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,278
Closed -$264K – 2104
2021
Q2 		$264K Buy
3,278
+2,198
+204% +$175K ﹤0.01% 1815
2021
Q1 		$90K Buy
+1,080
New +$110K ﹤0.01% 1991
2020
Q4 		– Sell
-1,748
Closed -$186K – 1956
2020
Q3 		$186K Buy
+1,748
New +$243K ﹤0.01% 1500

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Michael Gelband's AXDX Position: Q3 2021 in Review

Michael Gelband sold out of Accelerate Diagnostics (AXDX) in Q3 2021, closing a stake of 3,278 shares — an estimated $264K sold.

Michael Gelband first reported a position in AXDX in Q3 2020 and held it in 3 quarters. The position peaked at $264K in Q2 2021. 105 funds tracked by Wall St. Rank hold AXDX as of Q3 2021.

  • Michael Gelband reported no remaining Accelerate Diagnostics position as of Q3 2021 after selling out during the quarter.
  • Michael Gelband sold 3,278 Accelerate Diagnostics shares in Q3 2021, an estimated $264K.
  • Michael Gelband first reported a position in Accelerate Diagnostics in Q3 2020 and held it in 3 quarters.
  • Michael Gelband's Accelerate Diagnostics position peaked at $264K in Q2 2021.
  • 105 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q3 2021.

Based on ExodusPoint Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.